Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Abstract Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years ol...

Full description

Saved in:
Bibliographic Details
Main Authors: Oren Pasvolsky, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A. Davis, Aimaz Afrough, Mariola Vazquez-Martinez, Aishwarya Sannareddy, Utkarsh Goel, Rahul Banerjee, Jack Khouri, Frances Cervoni, Mahmoud R. Gaballa, Alex Lieberman-Cribbin, Masooma Shifa Rana, Kelley Julian, Christopher J. Ferreri, Leyla Shune, Shaun DeJarnette, Evguenia Bhurtel, Sandra Susanibar Adaniya, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Adriana Rossi, Megan M. Herr, Daniel Schrum, Chenyu Lin, Shahzad Raza, Yi Lin, Shonali Midha, Nadeem Omar, Shebli Atarsh, Joseph McGuirk, Douglas Sborov, Peter Voorhees, Faiz Anwer, Melissa Alsina, Ciara Freeman, Alfred L. Garfall, Beatrice M. Razzo, Surbhi Sidana, Andrew J. Cowan, Larry D. Anderson Jr, Doris K. Hansen, Shambavi Richard, Krina K. Patel, Hans C. Lee, Ariel Grajales-Cruz
Format: Article
Language:English
Published: Nature Publishing Group 2025-05-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-025-01297-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items